FTH1 and cancer: Collectively, our findings support the existence of a FHC-ROS-NF-κB axis, which would account for the acquired chemoresistant phenotype in K562 and SKOV3 cell line models, encourages a deeper investigation of the correlation between FHC expression in cancer tissues and clinical outcomes, and highlights the potentiality of FHC in cancer therapy.